BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
FOXP1
,
Metabolism of xenobiotics
,
Inflammatory disorder
,
Lymphocyte
,
Neocentromeres
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
tumor endothelial cells
Summary
General Info
Curated Studies
Most Correlated Studies
CD31+ and CD105+ tumor endothelial cells of hepatocellular carcinoma (HCC) patients
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Induction of KDR expression in bovine arterial endothelial cells by thrombin: involvement of nitric …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma
Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in R…
Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer
Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, …
Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells or Circ…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ